Ignite Creation Date:
2024-05-06 @ 1:29 PM
Last Modification Date:
2024-10-26 @ 1:14 PM
Study NCT ID:
NCT04032665
Status:
WITHDRAWN
Last Update Posted:
2022-07-18
First Post:
2019-07-18
Brief Title:
Reveal Transition - A Mechanistic Study in Transition Stabilized Phase of CAD
Sponsor:
University Hospital Tuebingen
Organization:
University Hospital Tuebingen
Study Overview
Official Title:
Reveal Transition Rivaroxaban-Evaluation of Variables Enhancing Antithrombotic Efficacy and Longterm-Outcome in Stabilized Patients With Cardiovascular Disease A Mechanistic Study in Transition Stabilized Phase of CAD
Status:
WITHDRAWN
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
study design reconsidered
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RevealTrans
Brief Summary:
Longterm oral anticoagulation with very low dose rivaroxaban 25mg bid in combination with aspirin has been shown superior over standard aspirin monotherapy in patients with stable coronary artery disease CAD in the COMPASS trial To date there are no data comparing these - antithrombotic strategies and to provide insights about mechanistic effects of very low dose rivaroxaban on top of aspirin for longterm treatment
Thus the goal of the planned pilot study will be to identify effects of rivaroxaban on platelet function platelet-mediated vascular inflammation and particularly platelet-mediated thrombin generation as well as the underlying mechanisms and to reveal differences in mechanistic effects during longterm treatment with combined novel antiplateletanticoagulant strategies This study is planned as descriptive study
Thus the goal of the planned pilot study will be to identify effects of rivaroxaban on platelet function platelet-mediated vascular inflammation and particularly platelet-mediated thrombin generation as well as the underlying mechanisms and to reveal differences in mechanistic effects during longterm treatment with combined novel antiplateletanticoagulant strategies This study is planned as descriptive study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None